| Biomarker ID | 461 |
| PMID | 19491931 |
| Year | 2009 |
| Biomarker | IGFBP3 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | NA |
| Subjects | Humans |
| Regulation | Higher concentrations in patients with decreased risk of advanced prostate cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.44 (95% CI: 0.25-0.77) |
| Effect on Pathways | Pathways Include:-Hypoxia and p53 in the cardiovascular system,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs),TAp63 pathway,Delta Np63 pathway,Ghrelin-mediated regulation of food intake and energy homeostasis |
| Experiment | Localised Vs Advanced Prostate Cancer |
| Type of Biomarker | Prognostic |
| Cohort | Meta analysis of 21 studies using, IGF1 and IGFBP3 as marker to predict advanced prostate cancer risk. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.004 |
| Method Used | NA |
| Clinical | No |
| Remarks | Metastudy |
| Clinical Trial Number | NA |
| Degree Of Validity | Metanalysis from 96 studies |
| Technical Name | IGFBP3 |